To put regulations on this matter, Central Drugs Standard Control Organisation (CDSCO) made a list of 294 FDCs, and directions are given to all State/UT Drug Controllers of India to withdraw 294 FDCs from the licensed market the consent of DCGI. Court then got it to stay order in favour of the Manufacturers Association
Indian pharma market is flooded with irrational Fixed Dose Combination (FDCs) and is an important topic for critical and scientific analysis. The country needs some regulatory laws for FDCs after analysing whether they are rational and genuinely required for our health care system. Now, the new FDCs proposed by the Government of India suggest certain effective measures to curb the menace for the first time in the country.
To put regulations on this matter, Central Drugs Standard Control Organisation (CDSCO) made a list of 294 FDCs, and directions are given to all State/UT Drug Controllers of India to withdraw 294 FDCs from the licensed market the consent of DCGI. Court then got it to stay order in favour of the Manufacturers Association. On 16 th January, 2008 this matter came up in the 56th meeting of Drugs Technical Advisory Board (DTAB). The subcommittee of DTAB looked into the matter. The report of DTAB was accepted by the court of law on 15 th December 2017. Presently, DTAB declared 83 FDCs Drugs as rational and notified the process to be followed by all the manufacturers and stakeholders for obtaining the manufacturing license.
According the recent notification dated 8 th September, 2020 any submission of product license issued by SLA indicating dosage and strength of FDC to any firm before 28.11.2007 will be considered final. On 29 th July, 2020, a report of DTAB was generated which depicts there are 3 more rational FDC combinations under 294 FDCs category. The challenges of the earlier notification are that there is no mention of strength and dosage forms in the list.
Sr No | Name of the FDC |
1. | Atenolol+Losartan+Hydrochlorothiazide |
2. | Duloxetine+Mecobalamin |
3. | Mecobalamin+Vit.B6+Folic Acid |
All the manufacturers who have licenses from SLA for these FDCs but don’t have NOC from DCGI, need to submit applications within 4 months to the Directorate.
Moreover, few manufacturers who have license by SLA for the above FDCs applied for approval. These manufacturers can give application by 31.03.2021.
Navigating Software as a Medical Device regulation involves addressing varying global standards, including risk-based classifications...
The future of Software as a Medical Device will see breakthroughs in Artificial Intelligence-based diagnostics, personalised treatments, and remote monitoring...
Software as a Medical Device refers to software applications designed for medical purposes, such as diagnosis, treatment, or monitoring, without being part of a physical device...
Please feel free to talk to us if you have any questions. We endeavour to answer within 24 hours.